These characteristics highlight the importance of the tumour-specific CD8+ T cell response generated by RB-treated LLCs and mDCs pulsed with RB-treated LLCs in vivo or ex vivo in antitumour immunity. The gene discussed is CD8A; the disease is neoplasm.